Home » Newsletters » BioWorld

BioWorld

Sep. 24, 2009

View Archived Issues

Nexavar Continues to Wow in Breast Cancer Combo Study

The data just keep getting better for Nexavar in breast cancer. (BioWorld Today) Read More

No-Vote Panel: Exalgo Approval Needs Tight Abuse Safeguards

Direct RNA Sequencing May Get at 'True Transcriptome' of Cell

Pair of Phase III Trials Upcoming, Spectrum Adds $50M to Coffers

DxS Acquisition Boosts Qiagen's Companion Diagnostics Portfolio

Clinic Roundup

Appointments And Advancements

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...